Rationale and design of MILES-3 and MILES-4 studies: Two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non-small-cell lung cancer

Clinical Lung Cancer

Volumn 15, Issue 2, 2014, Pages 166-170

  Gridelli, Cesare ^a   Rossi, Antonio ^a   Di Maio, Massimo ^b   Leo, Silvana ^c   Filipazzi, Virginio ^d   Favaretto, Adolfo G ^e   Burgio, Marco A ^f   Cinieri, Saverio ^g,h   Bianco, Roberto ⁱ   Ciardiello, Fortunato ^j   Cavanna, Luigi ^k   Bordonaro, Roberto ^l   Costanzo, Raffaele ^b   Sandomenico, Claudia ^b   Gallo, Ciro ^j   Perrone, Francesco ^b   Morabito, Alessandro ^b  

^a S G MOSCATI HOSPITAL   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c VITO FAZZI HOSPITAL   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^f DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^g A Perrino Hospital   (Italy)

^h EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

ⁱ UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^j SECOND UNIVERSITY OF NAPLES   (Italy)

^k GUGLIELMO DA SALICETO HOSPITAL   (Italy)

^l Garibaldi Nesima Hospital   (Italy)

more..

Author keywords

Advanced NSCLC; Cisplatin; Elderly; Gemcitabine; Pemetrexed; Randomized trial

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DEOXYCYTIDINE; GEMCITABINE; GLUTAMIC ACID DERIVATIVE; GUANINE; PEMETREXED;

ADENOCARCINOMA; AGED; ANALOGS AND DERIVATIVES; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LUNG NEOPLASMS; LYMPH NODE METASTASIS; MALE; METHODOLOGY; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROGNOSIS; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SECONDARY; SURVIVAL RATE;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; FEMALE; FOLLOW-UP STUDIES; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; RESEARCH DESIGN; SURVIVAL RATE;

EID: 84894087464     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2013.11.011     Document Type: Article

References (20)

1. J. Ferlay, H.R. Shin, and F. Bray et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 2010 2893 2917
2. T.K. Owonikoko, C.C. Ragin, and C.P. Belani et al. Lung cancer in elderly patients: an analysis of the Surveillance, Epidemiology, and End Results database J Clin Oncol 25 2007 5570 5577
3. Elderly Lung Cancer Vinorelbine Italian Study Group Effects of vinorelbine on quality of life and survival of elderly patients with advanced non small cell lung cancer J Natl Cancer Inst 91 1999 66 72
4. C. Gridelli, F. Perrone, and C. Gallo et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial J Natl Cancer Inst 95 2003 362 372
5. C.G. Azzoli, S. Baker Jr, and S. Temin et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer J Clin Oncol 27 2009 6251 6266
6. E. Felip, C. Gridelli, and P. Baas et al. Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy. 1st ESMO Consensus Conference in Lung Cancer, Lugano, 2010 Ann Oncol 22 2011 1507 1519
7. E. Quoix, G. Zalcman, and J.P. Oster et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial Lancet 378 2011 1079 1088
8. T. Abe, A. Yokoyama, and K. Takeda et al. Randomized phase III trial comparing weekly docetaxel (D)-cisplatin (P) combination with triweekly D alone in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): an intergroup trial of JCOG0803/WJOG4307L J Clin Oncol 29 15 suppl 2011 478s, abstract 7509
9. B. Biesma, A.N.M. Wymenga, and A. Vincent et al. Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3, a phase III study Ann Oncol 22 2011 1520 1527
10. C. Gridelli, P. Maione, and A. Illiano et al. Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies J Clin Oncol 25 2007 4663 4669
11. G.V. Scagliotti, P. Parikh, and J. von Pawel et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 2008 3543 3551
12. G. Scagliotti, T. Brodowicz, and F.A. Shepherd et al. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer J Thorac Oncol 6 2011 64 70
13. C. Shih, V.J. Chen, and L.S. Gossett et al. LY231514, a pyrrolo[2,3-D]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes Cancer Res 57 1997 1116 1123
14. E. Giovannetti, H.H. Backus, and D. Wouters et al. Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels Br J Cancer 96 2007 769 775
15. H.L. Gomez, S.L. Santillana, and C.S. Vallejos et al. A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression Clin Cancer Res 12 2006 832 838
16. M.G. Rose, M.P. Farrell, and J.C. Schmitz Thymidylate synthase: a critical target for cancer chemotherapy Clin Colorectal Cancer 1 2002 220 229
17. P. Ceppi, M. Volante, and S. Saviozzi et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase Cancer 107 2006 1589 1596
18. C. Gridelli, T. Brodowicz, and C.J. Langer et al. Pemetrexed therapy in elderly patients with good performance status: analysis of two phase III trials of patients with nonsquamous non-small cell lung cancer Clin Lung Cancer 13 2012 340 346
19. Response Evaluation Criteria in Solid Tumors. RECIST version 1.1. Available at: http://ctep.cancer.gov/protocolDevelopment/docs/recist-guideline. pdf. Accessed: December 16, 2013.
20. National Cancer Institute Common Terminology Criteria for Adverse Events. NCI CTC-AE version 4.0. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/About. html. Accessed: December 16, 2013.